Bezuclastinib + Sunitinib
Peak
Cogent Biosciences · Phase 3 · Recruiting · Enrollment 482
| Arm | Reported safety |
|---|---|
| Bezuclastinib 600 mg + sunitinib 37.5 mg | grade 3 or higher ALT/AST increased: 10.8%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 7.4%, data cutoff 09.30.2025 |
| Sunitinib 37.5 mg continuous | grade 3 or higher ALT/AST increased: 1.4%, data cutoff 09.30.2025discontinued for treatment-related adverse events: 3.8%, data cutoff 09.30.2025 |
A count stays a count. This page does not turn a count into a percent.